POLB 001 patent granted in South Africa
Poolbeg Pharma PLC has received notification of the official grant of its Immunomodulator II patent in South Africa for POLB 001, providing protection until December 2038 for the prevention of hypercytokinemia and severe influenza. This patent strengthens the company's intellectual property portfolio for POLB 001, a p38 MAP kinase inhibitor with potential applications in preventing cancer immunotherapy-induced Cytokine Release Syndrome and severe influenza, thereby enhancing its value and appeal to potential partners.
Select text to share a quote on X · sign in to keep highlights & notes in your POLB notes
POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza
Patent decision strengthens Poolbeg's intellectual property portfolio
30 June 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces it has received notification of the official decision to grant Poolbeg's Immunomodulator II patent in South Africa, providing protection for POLB 001 for the prevention of hypercytokinaemia and severe influenza until December 2038.
POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention of cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally.
Poolbeg has a robust portfolio of patents in place covering p38 MAP kinase inhibitors for the treatment of severe influenza; and for POLB 001 for the prevention of hypercytokinemia. Additional patent applications have been filed to strengthen and complement Poolbeg's POLB 001 patent portfolio, particularly for cancer immunotherapy-induced CRS. Developing a strong intellectual property portfolio remains a key priority for Poolbeg, enhancing POLB 001's value and appeal to potential partners.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented: "This latest patent grant reflects our commitment to further strengthen POLB 001's global IP portfolio, enhancing its value and attractiveness to prospective partners. POLB 001 holds the potential to significantly benefit patients and healthcare systems globally across multiple disease areas, and this patent represents another step forward in our mission to positively impact the lives of patients."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.